SCHEMBL3140979

SCHEMBL3140979

Cc1ccc(NC(=O)c2ccc(N3CCN(C)CC3)c(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 19/20 0.79
MAP4K2 Q12851 19/20 0.79
BMX P51813 3/20 0.73
ABL1 P00519 3/20 0.73
LCK P06239 1/20 0.73
FES P07332 1/20 0.73
RET P07949 1/20 0.73
PDGFRB P09619 1/20 0.73
KIT P10721 1/20 0.73
FGFR1 P11362 1/20 0.73
SRC P12931 1/20 0.73
PDGFRA P16234 1/20 0.73
FLT1 P17948 1/20 0.73
FGFR3 P22607 1/20 0.73
EPHA3 P29320 1/20 0.73
KDR P35968 1/20 0.73
EPHB4 P54760 1/20 0.73
TEK Q02763 1/20 0.73
KARS1 Q15046 1/20 0.73
NTRK3 Q16288 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3129806 0.94 TNK2 (0.70) TNK2MAP4K2BMXABL1LCK
SCHEMBL3134112 0.94 TNK2 (0.70) TNK2MAP4K2BMXABL1LCK
SCHEMBL4868974 0.92 TNK2 (0.67) TNK2MAP4K2BMXABL1LCK
SCHEMBL3139613 0.91 TNK2 (0.83) TNK2MAP4K2BMXABL1LCK
SCHEMBL3132781 0.88 TNK2 (0.80) TNK2MAP4K2BMXABL1LCK
SCHEMBL13523237 0.88 TNK2 (0.67) TNK2MAP4K2BMXABL1LCK
SCHEMBL3143280 0.88 TNK2 (0.70) TNK2MAP4K2BMXABL1LCK
SCHEMBL4867438 0.87 TNK2 (0.61) TNK2MAP4K2BMXABL1LCK
SCHEMBL3139851 0.87 TNK2 (0.76) TNK2MAP4K2BMXABL1LCK
SCHEMBL31264587 0.85 TNK2 (0.61) TNK2MAP4K2BMXABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
EP-1651648-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-09-02 EP disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US disclosed
EP-1651648-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-03 EP disclosed
WO-2005011597-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BMX, FES, FRK TNK2 203/4885MAP4K2 37/4885BMX 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.